Innate Pharma S.A.
IPHA
$2.03
$0.021.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -75.77% | -75.93% | -75.67% | -60.62% | -42.32% |
| Total Other Revenue | -25.33% | -25.07% | -22.99% | -9.43% | 6.54% |
| Total Revenue | -62.43% | -65.98% | -67.34% | -52.41% | -34.36% |
| Cost of Revenue | -18.59% | -13.87% | -7.18% | -6.15% | -5.00% |
| Gross Profit | -56.06% | -336.32% | -668.29% | -10,227.66% | -298.45% |
| SG&A Expenses | 6.90% | 5.94% | 7.84% | 3.65% | -0.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.99% | -8.88% | -3.48% | -3.72% | -3.84% |
| Operating Income | -32.19% | -97.57% | -306.86% | -146.66% | -62.26% |
| Income Before Tax | -36.03% | -127.42% | -552.82% | -25.72% | 41.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.03% | -127.42% | -552.82% | -25.72% | 41.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.03% | -127.42% | -552.82% | -25.62% | 42.01% |
| EBIT | -32.19% | -97.57% | -306.86% | -146.66% | -62.26% |
| EBITDA | -35.69% | -118.06% | -488.70% | -229.23% | -106.96% |
| EPS Basic | -31.18% | -123.17% | -549.90% | -23.58% | 42.94% |
| Normalized Basic EPS | -31.13% | -123.08% | -549.92% | -174.24% | -49.87% |
| EPS Diluted | -31.08% | -122.24% | -542.55% | -23.40% | 42.87% |
| Normalized Diluted EPS | -31.13% | -122.44% | -541.84% | -172.53% | -49.24% |
| Average Basic Shares Outstanding | 4.16% | 2.45% | 0.74% | 0.88% | 1.01% |
| Average Diluted Shares Outstanding | 4.16% | 0.71% | -2.01% | -1.89% | -1.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |